In the ongoing LOGIC-2 phase II clinical trial (https://clinicaltrials.gov/ct2/show/NCT02159066) for advanced BRAF melanomas, one of the FGFR1–3 selective inhibitors, BGJ398 (Infigratinib), was included as the third agent used in combination with LGX818 (Encorafenib), a potent BRAF inhibitor, and MEK162 (Binimetinib), a selective inhibitor of MEK. The gene discussed is MAP2K7; the disease is melanoma.